Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients

Astellas

Status: Completed

Conditions: Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis

Treatments: Drug: Kiklin capsules

Study type: Observational

Funder types: Industry

Identifiers

NCT01901107

KIK001

Details and patient eligibility

About

The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.

Full description

Bixalomer is administered at initial oral dosage of 500 mg three times a day just before a meal. The dosage can be adjusted based on symptoms and serum phosphorus level.

Enrollment: 1,078 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Chronic renal failure patients with hyperphosphataemia receiving hemodialysis

Trial design

1,078 participants in 1 patient group

Kiklin group

Treatment:

Drug: Kiklin capsules